Semaglutide improves liver enzymes and fatty liver index in patients with obesity and cardiovascular disease – results from the SELECT trial
Sebastian M. Meyhöfer1,2; Bertrand Cariou3; Cintia Cercato4; Helen M. Colhoun5; John E. Deanfield6; Mette Skalshøi Kjær7; Ole Kleist Jeppesen7; A. Michael Lincoff8; Ildiko Lingvay9; Philip N. Newsome10; Stephen J. Nicholls11; Maria De Los Angeles Quiroga Pelaez7; Ferruccio Santini12; Arun J. Sanyal13; Steven E. Kahn14
MATERIALS AVAILABLE
Slide
Poster
Saturday, 16 November 2024
08:00 - 17:00
PST
2302
Publication
Exploring predictors of rapid progression to major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease
Ying Shang1; Johan Vessby2; Kamal Kant Mangla3; Riku Ota4; Marc Künkel Winther4; Mattias Ekstedt5; Hannes Hagström1,6
MATERIALS AVAILABLE
Poster
Video
13:00 - 14:00
PST
2305
Publication
Understanding Metabolic Dysfunction-Associated Steatohepatitis: Differences in Clinical and Demographic Characteristics Across Racial and Ethnic Groups
Andrea R. Mospan1; Breda Munoz1; Heather L. Morris1; Aarth Sheth2; Rakesh Luthra2
MATERIALS AVAILABLE
Poster
Video
Tuesday, 19 November 2024
11:20 - 11:30
PST
Publication
Phase 3 ESSENCE trial: Semaglutide in metabolic dysfunction-associated steatohepatitis
P.N. Newsome1,2; A.J. Sanyal3; I. Kliers4; L.H Østergaard4; M.T. Long4; M.S. Kjær4; A.M.G. Cali4; E. Bugianesi5; M. Rinella6; M. Roden7,8,9; V. Ratziu10